The role of surgery in advanced renal cell carcinoma: Cytoreductive nephrectomy and metastasectomy

Hematology/Oncology Clinics of North America

Volumn 25, Issue 4, 2011, Pages 753-764

  Karam, Jose A ^a   Wood, Christopher G ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Advanced renal cell carcinoma; Cytoreduction; Metastasectomy; Nephrectomy

Indexed keywords

BEVACIZUMAB; INTERLEUKIN 2; LACTATE DEHYDROGENASE; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

BONE METASTASIS; BRAIN DAMAGE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CYTOREDUCTIVE SURGERY; DRUG EFFECT; HEMATURIA; HUMAN; IMMUNOTHERAPY; KIDNEY CARCINOMA; KIDNEY INJURY; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER METASTASIS; LIVER RESECTION; LUNG LESION; METASTASECTOMY; NEPHRECTOMY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RADIOFREQUENCY ABLATION; REVIEW; STEREOTACTIC RADIOSURGERY; SURGICAL TECHNIQUE; SURVIVAL RATE; TUMOR VOLUME;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; COMBINED MODALITY THERAPY; HUMANS; KIDNEY NEOPLASMS; NEOPLASM METASTASIS; NEPHRECTOMY; PROGNOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 79960379717     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2011.05.002     Document Type: Review

References (50)

1. Parkin D.M., Bray F., Ferlay J., et al. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74.
2. Motzer R.J., Bander N.H., Nanus D.M. Renal-cell carcinoma. N Engl J Med 1996, 335:865.
3. Motzer R.J., Mazumdar M., Bacik J., et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999, 17:2530.
4. Fallick M.L., McDermott D.F., LaRock D., et al. Nephrectomy before interleukin-2 therapy for patients with metastatic renal cell carcinoma. J Urol 1997, 158:1691.
5. Leibovich B.C., Han K.R., Bui M.H., et al. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 2003, 98:2566.
6. Lara P.N., Tangen C.M., Conlon S.J., et al. Predictors of survival of advanced renal cell carcinoma: long-term results from Southwest Oncology Group Trial S8949. J Urol 2009, 181:512.
7. Heng D.Y., Xie W., Regan M.M., et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009, 27:5794.
8. Choueiri T.K., Garcia J.A., Elson P., et al. Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer 2007, 110:543.
9. Flanigan R.C., Salmon S.E., Blumenstein B.A., et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001, 345:1655.
10. Mickisch G.H., Garin A., van Poppel H., et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001, 358:966.
11. Flanigan R.C., Mickisch G., Sylvester R., et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 2004, 171:1071.
12. Zini L., Capitanio U., Perrotte P., et al. Population-based assessment of survival after cytoreductive nephrectomy versus no surgery in patients with metastatic renal cell carcinoma. Urology 2009, 73:342e6.
13. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356:125.
14. Escudier B., Pluzanska A., Koralewski P., et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007, 370:2103.
15. Motzer R.J., Escudier B., Oudard S., et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008, 372:449.
16. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007, 356:115.
17. Rini B.I., Halabi S., Rosenberg J.E., et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008, 26:5422.
18. Hudes G., Carducci M., Tomczak P., et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007, 356:2271.
19. Choueiri T.K., Xie W., Kollmannsberger C., et al. The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J Urol 2011, 185:60.
20. Bellmunt J. Future developments in renal cell carcinoma. Ann Oncol 2009, 20(Suppl 1):i13.
21. Biswas S., Kelly J., Eisen T. Cytoreductive nephrectomy in metastatic clear-cell renal cell carcinoma: perspectives in the tyrosine kinase inhibitor era. Oncologist 2009, 14:52.
22. Abel E.J., Culp S.H., Tannir N.M., et al. Primary tumor response to targeted agents in patients with metastatic renal cell carcinoma. Eur Urol 2011, 59:10.
23. Culp S.H., Tannir N.M., Abel E.J., et al. Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy?. Cancer 2010, 116:3378.
24. Krambeck A.E., Leibovich B.C., Lohse C.M., et al. The role of nephron sparing surgery for metastatic (pM1) renal cell carcinoma. J Urol 2006, 176:1990.
25. Hutterer G.C., Patard J.J., Colombel M., et al. Cytoreductive nephron-sparing surgery does not appear to undermine disease-specific survival in patients with metastatic renal cell carcinoma. Cancer 2007, 110:2428.
26. Capitanio U., Zini L., Perrotte P., et al. Cytoreductive partial nephrectomy does not undermine cancer control in metastatic renal cell carcinoma: a population-based study. Urology 2008, 72(5):1090-1095.
27. Walther M.M., Lyne J.C., Libutti S.K., et al. Laparoscopic cytoreductive nephrectomy as preparation for administration of systemic interleukin-2 in the treatment of metastatic renal cell carcinoma: a pilot study. Urology 1999, 53:496.
28. Eisenberg M.S., Meng M.V., Master V.A., et al. Laparoscopic versus open cytoreductive nephrectomy in advanced renal-cell carcinoma. J Endourol 2006, 20:504.
29. Finelli A., Kaouk J.H., Fergany A.F., et al. Laparoscopic cytoreductive nephrectomy for metastatic renal cell carcinoma. BJU Int 2004, 94:291.
30. Matin S.F., Madsen L.T., Wood C.G. Laparoscopic cytoreductive nephrectomy: the M. D. Anderson Cancer Center experience. Urology 2006, 68:528.
31. Karam J.A., Ahrar K., Wood C.G., et al. Radio frequency ablation of renal tumors in patients with metastatic renal cell carcinoma. J Urol 2010, 184:1882.
32. Eggener S.E., Yossepowitch O., Kundu S., et al. Risk score and metastasectomy independently impact prognosis of patients with recurrent renal cell carcinoma. J Urol 2008, 180:873.
33. Alt A.L., Boorjian S.A., Lohse C.M., et al. Survival after complete surgical resection of multiple metastases from renal cell carcinoma. Cancer 2011, [Epub ahead of print].
34. Karam J.A., Rini B.I., Varella L., et al. Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma. J Urol 2011, 185:439.
35. Durr H.R., Maier M., Pfahler M., et al. Surgical treatment of osseous metastases in patients with renal cell carcinoma. Clin Orthop Relat Res 1999, (367):283.
36. Jackson R.J., Loh S.C., Gokaslan Z.L. Metastatic renal cell carcinoma of the spine: surgical treatment and results. J Neurosurg 2001, 94:18.
37. Jung S.T., Ghert M.A., Harrelson J.M., et al. Treatment of osseous metastases in patients with renal cell carcinoma. Clin Orthop Relat Res 2003, (409):223.
38. Vecil G.G., Lang F.F. Surgical resection of metastatic intraventricular tumors. Neurosurg Clin N Am 2003, 14:593.
39. Wronski M., Arbit E., Russo P., et al. Surgical resection of brain metastases from renal cell carcinoma in 50 patients. Urology 1996, 47:187.
40. Shuch B., La Rochelle J.C., Klatte T., et al. Brain metastasis from renal cell carcinoma: presentation, recurrence, and survival. Cancer 2008, 113:1641.
41. Stief C.G., Jahne J., Hagemann J.H., et al. Surgery for metachronous solitary liver metastases of renal cell carcinoma. J Urol 1997, 158:375.
42. Alves A., Adam R., Majno P., et al. Hepatic resection for metastatic renal tumors: is it worthwhile?. Ann Surg Oncol 2003, 10:705.
43. Assouad J., Petkova B., Berna P., et al. Renal cell carcinoma lung metastases surgery: pathologic findings and prognostic factors. Ann Thorac Surg 2007, 84:1114.
44. Cerfolio R.J., Allen M.S., Deschamps C., et al. Pulmonary resection of metastatic renal cell carcinoma. Ann Thorac Surg 1994, 57:339.
45. Hofmann H.S., Neef H., Krohe K., et al. Prognostic factors and survival after pulmonary resection of metastatic renal cell carcinoma. Eur Urol 2005, 48:77.
46. Murthy S.C., Kim K., Rice T.W., et al. Can we predict long-term survival after pulmonary metastasectomy for renal cell carcinoma?. Ann Thorac Surg 2005, 79:996.
47. Pfannschmidt J., Hoffmann H., Muley T., et al. Prognostic factors for survival after pulmonary resection of metastatic renal cell carcinoma. Ann Thorac Surg 2002, 74:1653.
48. Piltz S., Meimarakis G., Wichmann M.W., et al. Long-term results after pulmonary resection of renal cell carcinoma metastases. Ann Thorac Surg 2002, 73:1082.
49. Tanis P.J., van der Gaag N.A., Busch O.R., et al. Systematic review of pancreatic surgery for metastatic renal cell carcinoma. Br J Surg 2009, 96:579.
50. Iesalnieks I., Winter H., Bareck E., et al. Thyroid metastases of renal cell carcinoma: clinical course in 45 patients undergoing surgery. Assessment of factors affecting patients' survival. Thyroid 2008, 18:615.